1 |
刘烈华, 李延兵. 2型糖尿病的缓解:百家争鸣与脚踏实地[J]. 实用医学杂志, 2024, 40(16): 2206-2210.
|
2 |
FURUSAWA S, NOMOTO H, YOKOYAMA H, et al. Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: a multicentre, prospective, randomized, open-label, parallel-group comparison study (switch-sema 2 study)[J]. Diabetes Obes Metab, 2024, 26(3): 961-970.
|
3 |
鲁可, 陈小燕. 体质量管理在糖尿病防治中的利与弊[J]. 实用医学杂志, 2024, 40(16): 2219-2223.
|
4 |
FRIAS J P, DEENADAYALAN S, ERICHSEN L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: A multicentre, randomised, double-blind, active-controlled, phase 2 trial[J]. Lancet, 2023, 402(10403): 720-730. doi:10.1016/s0140-6736(23)01163-7
doi: 10.1016/s0140-6736(23)01163-7
|
5 |
HEISE T, MARI A, DEVRIES J H, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: A multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial[J]. Lancet Diabetes Endocrinol, 2022, 10(6): 418-429. doi:10.1016/s2213-8587(22)00085-7
doi: 10.1016/s2213-8587(22)00085-7
|
6 |
SHEN S, LIAO Q, WONG Y K, et al. The role of melatonin in the treatment of type 2 diabetes mellitus and alzheimer's disease[J]. Int J Biol Sci, 2022, 18(3): 983-994. doi:10.7150/ijbs.66871
doi: 10.7150/ijbs.66871
|
7 |
TAYLOR R, BARNES A C, HOLLINGSWORTH K G, et al. Aetiology of type 2 diabetes in people with a 'normal' body mass index: testing the personal fat threshold hypothesis[J]. Clin Sci (Lond), 2023, 137(16): 1333-1346. doi:10.1042/cs20230586
doi: 10.1042/cs20230586
|
8 |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
|
9 |
BARREA L, VETRANI C, CAPRIO M, et al. Nutritional management of type 2 diabetes in subjects with obesity: An international guideline for clinical practice[J]. Crit Rev Food Sci Nutr, 2023, 63(16): 2873-2885. doi:10.1080/10408398.2021.1980766
doi: 10.1080/10408398.2021.1980766
|
10 |
KARAGIANNIS T, MALANDRIS K, AVGERINOS I, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials[J]. Diabetologia, 2024, 67(7): 1206-1222. doi:10.1007/s00125-024-06144-1
doi: 10.1007/s00125-024-06144-1
|
11 |
BLÜHER M, ROSENSTOCK J, HOEFLER J, et al. Dose-response effects on hba1c and bodyweight reduction of survodutide, a dual glucagon/glp-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: A randomised clinical trial[J]. Diabetologia, 2024, 67(3): 470-482. doi:10.1007/s00125-023-06053-9
doi: 10.1007/s00125-023-06053-9
|
12 |
CAPEHORN M S, CATARIG A M, FURBERG J K, et al. Efficacy and safety of once-weekly semaglutide 1. 0mg vs once-daily liraglutide 1, 2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)[J]. Diabetes Metab, 2020, 46(2): 100-109. doi:10.1016/j.diabet.2019.101117
doi: 10.1016/j.diabet.2019.101117
|
13 |
KADOWAKI T, ISENDAHL J, KHALID U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east asian population (step 6): A randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial[J]. Lancet Diabetes Endocrinol, 2022, 10(3): 193-206. doi:10.1016/s2213-8587(22)00008-0
doi: 10.1016/s2213-8587(22)00008-0
|
14 |
FRÍAS J P, AUERBACH P, BAJAJ H S, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (sustain forte): A double-blind, randomised, phase 3b trial[J]. Lancet Diabetes Endocrinol, 2021, 9(9): 563-574. doi:10.1016/s2213-8587(21)00174-1
doi: 10.1016/s2213-8587(21)00174-1
|
15 |
JI L, DONG X, LI Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in sustain china: A 30-week, double-blind, phase 3a, randomized trial[J]. Diabetes Obes Metab, 2021, 23(2): 404-414. doi:10.1111/dom.14232
doi: 10.1111/dom.14232
|
16 |
STRAIN W D, FRENKEL O, JAMES M A, et al. Effects of semaglutide on stroke subtypes in type 2 diabetes: Post hoc analysis of the randomized sustain 6 and pioneer 6[J]. Stroke, 2022, 53(9): 2749-2757. doi:10.1161/strokeaha.121.037775
doi: 10.1161/strokeaha.121.037775
|
17 |
MCGUIRE D K, BUSUI R P, DEANFIELD J, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of soul, a randomized trial[J]. Diabetes Obes Metab, 2023, 25(7): 1932-1941.
|
18 |
WANG F, MAO Y, WANG H, et al. Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials[J]. Clin Drug Investig, 2022, 42(1): 17-28. doi:10.1007/s40261-021-01110-w
doi: 10.1007/s40261-021-01110-w
|
19 |
FRANCE N L, SYED Y Y. Tirzepatide: A review in type 2 diabetes[J]. Drugs, 2024, 84(2): 227-238. doi:10.1007/s40265-023-01992-4
doi: 10.1007/s40265-023-01992-4
|
20 |
STRETTON B, KOVOOR J, BACCHI S, et al. Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: A systematic review[J]. Intern Med J, 2023, 53(8): 1311-1320. doi:10.1111/imj.16126
doi: 10.1111/imj.16126
|
21 |
AZURI J, HAMMERMAN A, ABOALHASAN E, et al. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis[J]. Diabetes Obes Metab, 2023, 25(4): 961-964. doi:10.1111/dom.14940
doi: 10.1111/dom.14940
|
22 |
王若, 刘艳洁, 卢新卫, 等. 司美格鲁肽治疗超重2型糖尿病患者的临床研究[J]. 中国临床药理学杂志, 2023, 39(21): 3053-3057.
|
23 |
赵子明, 马琪, 陈俭, 等. 司美格鲁肽注射液对不稳定型心绞痛合并糖尿病患者冠脉介入术预后的影响[J]. 实用医学杂志, 2024, 40(24): 3515-3520.
|
24 |
KELLERER M, KALTOFT M S, LAWSON J, et al. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (sustain 11): A randomized, open-label, multinational, phase 3b trial[J]. Diabetes Obes Metab, 2022, 24(9): 1788-1799.
|
25 |
SINGH G, KRAUTHAMER M, BJALME-EVANS M. Wegovy (semaglutide): A new weight loss drug for chronic weight management[J]. J Investig Med, 2022, 70(1): 5-13. doi:10.1136/jim-2021-001952
doi: 10.1136/jim-2021-001952
|
26 |
MANN J F E, ROSSING P, BAKRIS G, et al. Effects of semaglutide with and without concomitant sglt2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the flow trial[J]. Nat Med, 2024, 30(10): 2849-2856. doi:10.1038/s41591-024-03133-0
doi: 10.1038/s41591-024-03133-0
|
27 |
HEISE T, DEVRIES J H, URVA S, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes[J]. Diabetes Care, 2023, 46(5): 998-1004. doi:10.2337/dc22-1710
doi: 10.2337/dc22-1710
|